MDS Inc.
MDS Inc. of Toronto will acquire Molecular Devices Corp. of Sunnyvale, Calif., a manufacturer of cellular analysis and biochemical testing products for drug discovery and other life sciences applications. The deal is worth $615 million in cash, including $585 million for the purchase of outstanding shares and $30 million for outstanding stock options. The Canadian company intends to combine Molecular Devices and MDS Sciex to create a business unit with more than 1100 employees. Molecular Devices’ cellular analysis and biochemical screening products will retain their brand names, and MDS Sciex will continue to expand its mass spectrometry franchise.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024